A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Novartis
Montefiore Medical Center
Mayo Clinic
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center